Evaluation the validity of Interleukin-17 in Nephrotic Syndrome patients

Abstract

Background: The Nephrotic Syndrome (NS) is a clinical condition characterized via severe proteinuria, which causes hyperlipidemia, hypoalbuminemia, and edema, and other problems. It is produced by basement membrane is more permeable as a result of the damage of the renal glomerulus. Essentially, it occurs when there is an abnormality in glomerular permeability, which can be due to an intrinsic renal disease or secondary to congenital infections, diabetes, systemic lupus erythematosus, or neoplasia. Materials and methods: The research study was conducted on 70 randomly selected participants (35 Females and 35 Males) with autoimmune disease and nephrotic syndrom attending the kidney disease center in AlSadder Teaching City in AlNajaf province, Iraq. It was carried out from December 2022 to July 2023. The age of patients was range of 1-50y. Results: show a significant escalation (P≤ 0.05) in Interleukin level in nephrotic patients in comparing with control groups also a significant rise (P≤ 0.05) in Interleukin (IL)-17 level in nephrotic patients at Various ages groups in comparison to the various age groups of control groups and results moreover demonstrate significant effect (p≥ 0.05) in Interleukin (IL)-17 level between groups of ages. reveal no significant effect (P≥ 0.05) in Interleukin (IL)-17 level in females and males in nephrotic patients furthermore show a significant increase (P≤ 0.05) in Interleukin level in nephrotic patients in rural groups than urban groups. Conclusion: concluded that Interleukin-17 highly elevated and in patients with nephrotic syndrome, this factor is also linked to disease severity.